RSV, COVID-19, Flu Hospitalizations Declining in February 2024 Precision Vaccinations News – Precision Vaccinations

Atlanta (Precision Vaccinations News)

According to the U.S. government, the current respiratory season is ending with less impact on hospitalization than last year.

The combined weekly hospitalization rate for COVID-19 and influenza from theNational Healthcare Safety Network during the week of December 30, 2023, was 87.5% of 2022'speak (16.8 vs 19.2 admissions per 100,000).

On February 8, 2024, the Centers for Disease Control and Prevention (CDC) published potentially its last Outlook regarding respiratory disease for the remainder of the 2023-2024 season.

The CDC anticipates that total hospitalizations for COVID-19, influenza, and RSV will decline but remain elevated into February 2024.

The CDC wrote, 'We do not anticipate producing additional respiratory disease outlooks during the remainder of the 2023-2024 season. We continue to monitor respiratory diseases and will update this Outlook should we identify any unusual events, such as a significant resurgence ofthese diseases.'

The final CDC Outlook is based on expert judgment, historical data, and scenario modeling.

From a prevention perspective, the CDC confirmed ample supplies of respiratory vaccines and antibody therapies are available at most clinics and pharmacies in the U.S.

Original post:

RSV, COVID-19, Flu Hospitalizations Declining in February 2024 Precision Vaccinations News - Precision Vaccinations

Related Posts
Tags: